Stock News & Analysis

The business fundamentals and valuation are slowly converging on each other.

The Schwab U.S. Dividend Equity ETF and the Vanguard Total Stock Market ETF are both terrific funds. But one has the edge in terms of long-term growth potential.

Angel Oak UltraShort Income ETF offers a higher-yielding alternative to money market funds, with a diversified portfolio of short-duration fixed income and securitized credit.

Intuitive Surgical's success hints that this competitor could have more growth potential than investors think.

There's no perfect time to rebalance your portfolio. But there might be a right time for you. Maybe it's right now, and maybe it's not.

The world's getting more chaotic by the day, but these stocks should add some much-appreciated peace to your portfolio.

The membership-based wholesale retailer keeps stringing together impressive monthly updates.

Beyond Meat stock was hot in April, but it's giving up gains this month.

These companies have what investors want.

The world is facing a growing oil supply shortfall.

Cloud revenue is just one part of the story for both tech giants.

This young rare-earth miner now owns one of the world's largest rare-earth deposits.

The credit card giant is still an evergreen investment.

A partnership with an AI leader has investors excited.

Snowflake and SoundHound AI could recover from their recent declines.

Oshkosh stock could be a buy -- if it can restart its growth engine.

The incredible demand for storage in data centers has been a tailwind for Western Digital, and the good news is that its red-hot rally is far from being over.

The iShares MSCI All Country Asia ex Japan ETF (AAXJ) provides targeted exposure to Asian equities outside Japan, distinguishing it from broad international funds. This distinction is significant, as returns are influenced by the performance of specific Asian markets rather than overall global equity trends.

HubSpot had a less-than-perfect earnings report, which amplified AI fears.

NuScale has design approval, but Oklo could reach commercialization sooner.